Patents by Inventor Josephine Juettner

Josephine Juettner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutical tools and methods for treating blindness by targeting photoreceptors
    Patent number: 11931427
    Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 19, 2024
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Josephine Juettner, Dasha Nelidova, Botond Roska
  • Expression cassette with a SynP160 promoter
    Patent number: 11883507
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: January 30, 2024
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • SYNP161, a promoter for the expression of genes
    Patent number: 11857642
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 150 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 2, 2024
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • Primate retinal pigment epithelium cell-specific promoter
    Patent number: 11739349
    Abstract: The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 400 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 29, 2023
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Josephine Juettner, Jacek Krol, Botond Roska
  • SynP61, A PRIMATE RETINAL PIGMENT EPITHELIUM CELL-SPECIFIC PROMOTER
    Publication number: 20230193314
    Abstract: The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 1500 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 22, 2023
    Inventors: Josephine JUETTNER, Jacek KROL, Botond ROSKA
  • SYNP162, a promoter for the expression of genes
    Patent number: 11608365
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: March 21, 2023
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • SynP159, a promoter for the expression of genes
    Patent number: 11591618
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 28, 2023
    Assignee: Friedrich Miescher Institute for BioMedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • SynPIII, a promoter for the specific expression of genes in retinal pigment epithelium
    Patent number: 11591615
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells of the retinal pigment epithelium of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: February 28, 2023
    Assignee: Friedrich Miescher Institute for BioMedical Research
    Inventors: Josephine Juettner, Jacek Krol, Botond Roska
  • SynP198, a promoter for the specific expression of genes in direction selective retinal ganglion cells
    Patent number: 11525145
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in direction selective retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: December 13, 2022
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • SYNP88, A PROMOTER FOR THE EXPRESSION OF GENES
    Publication number: 20220267800
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: May 13, 2022
    Publication date: August 25, 2022
    Inventors: Botond ROSKA, Josephine JUETTNER
  • SYNP88, a promoter for the specific expression of genes in retinal ganglion cells
    Patent number: 11371060
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: June 28, 2022
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond Roska, Josephine Juettner
  • PROMOTER FOR THE EXPRESSION OF GENES
    Publication number: 20220186214
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: January 7, 2022
    Publication date: June 16, 2022
    Inventors: Josephine JUETTNER, Botond ROSKA
  • COMPOSITIONS AND METHODS TO TREAT BIETTI CRYSTALLINE DYSTROPHY
    Publication number: 20220154211
    Abstract: Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
    Type: Application
    Filed: February 24, 2020
    Publication date: May 19, 2022
    Inventors: Christie L. BELL, Josephine JUETTNER, Jacek KROL, Terri MCGEE, Botond ROSKA
  • COMPOSITIONS AND METHODS TO TREAT BIETTI CRYSTALLINE DYSTROPHY
    Publication number: 20220154210
    Abstract: Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
    Type: Application
    Filed: February 24, 2020
    Publication date: May 19, 2022
    Inventors: Christie L. BELL, Josephine JUETTNER, Jacek KROL, Terri MCGEE, Botond ROSKA
  • SYNP5 (PROA9), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS
    Publication number: 20220119841
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to nucleic acid sequence coding for said gene.
    Type: Application
    Filed: January 23, 2020
    Publication date: April 21, 2022
    Inventors: Josephine JUETTNER, Jacek KROL, Botond ROSKA
  • SYNP35 (PROC8), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS
    Publication number: 20220119807
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: January 23, 2020
    Publication date: April 21, 2022
    Inventors: Josephine JUETTNER, Jacek KROL, Botond ROSKA
  • SYNP66 (PROA21), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS
    Publication number: 20220090062
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: January 23, 2020
    Publication date: March 24, 2022
    Inventors: Josephine JUETTNER, Jacek KROL, Botond ROSKA
  • Promoter for the specific expression of genes in retinal endothelial cells
    Patent number: 11254934
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: February 22, 2022
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Josephine Juettner, Botond Roska
  • SYNP17 (PROB1), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS
    Publication number: 20210395750
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 350 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 23, 2021
    Inventors: Josephine JUETTNER, Jacek KROL, Botond ROSKA
  • SYNP27 (PROB12), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PROTOPLASMIC ASTROCYTES
    Publication number: 20210388385
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 800 bp having at least 80% identity to said sequence of SEQ ID NO:1, and related uses, wherein said isolated nucleic acid molecule specifically leads to the expression in protoplasmic astrocytes of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 16, 2021
    Inventors: Josephine JUETTNER, Jacek KROL, Botond ROSKA